West Virginia Advances Model Rules; 2022 Implementation Hinges On Legislature

After a failed attempt last year to adopt a group of drug-related model rules that every other racing jurisdiction in the mid-Atlantic region has already implemented, the West Virginia Racing Commission (WVRC) on Monday voted 2-0 to advance to the state legislature new regulations concerning medication abuse and stepped-up penalty scales.

The July 12 passage of new rules concerning clenbuterol, non-steroidal anti-inflammatory drugs, intra-articular injections and the adoption of the most current Uniform Classification Guidelines for Foreign Substances list did not come without drama and several detours.

In fact, much of the wide-ranging debate centered not on the actual rules themselves, but on over-arching reasons for whether the board should even be voting on the rules package at all.

Back at the May 18 WVRC meeting, when the rules package was approved and sent out for its public commentary period, chairman Ken Lowe, Jr. said he would not support the system of fines included within some of those Association of Racing Commissioners International (ARCI) model rules because he believed they were too onerous for West Virginia trainers to bear.

Yet at Monday's meeting, Lowe didn't follow through on his vow to tinker with the penalty system.

“You can't pick on every little bitty nanogram out of a 1,200-pound animal when thereĀ  are people out there doing things that are a lot worse,” Lowe said.

“I hope every cheater gets caught and is suspended from the game–the big stuff, not the minor stuff, if it is an error,” Lowe said. “I'm not trying to convolute all this stuff–I swear I'm not. I'm just trying to help people understand that it's the bad people that I want to get caught and [be put] out of business. It's not the ones that screw up slightly or overlook something.”

Prior to the vote, Kelli Talbott, an attorney representing WVRC, advocated that board members seriously consider the model rules, lest West Virginia remain out of step.

“For what it's worth, we're the only mid-Atlantic state that does not have these,” Talbott said.

“I understand, commissioner Lowe, you pointed out that we should be mindful [that] West Virginia is different in some ways, that we should take that into account,” Talbott said. “But on the other hand, when you have [neighboring] states now having had these rules for a year or more…that's a concern.”

Talbott also pointed out that the commission “can't ignore the elephant in the room,” which is the Horseracing Integrity and Safety Act [HISA].

The federal regulatory system that will be created by that law is scheduled to go into effect July 1, 2022, and Talbott said it would supersede existing state regulations pertaining to racing (West Virginia is a plaintiff in a lawsuit trying to keep HISA from being implemented).

“You just have to be somewhat mindful of looking at what's going on at the federal level,” Talbott said. “I think it's highly likely that HISA will adopt rules that look a whole lot like these model rules that [we're proposing] and other states already have.”

Talbott also told commissioners that the governor in June had handed down a streamlining mandate telling state agencies to only send rule proposals to the legislature that were “deemed necessary.” She also noted that West Virginia's horsemen's groups had filed written comments opposing the model rules, which could lead to a “battle in legislature.” And even if the model rules do get adopted by the legislature, it will be about a year before they are actually implemented at the state's two Thoroughbred tracks.

“At this point, I don't think we can deny that West Virginia's an outlier in the mid-Atlantic with regard to these rules,” Talbott said. “But on the other hand, you have opposition from the horsemen, you have the governor's executive order, you have the HISA implementation. And so I think the legitimate question is, 'Is it really something that you want to take on this year?'”

Lowe responded to Talbott's briefing by reminding her that it was not her place to advocate one way or the other for model rules.

“I'll say this in all due respects: The commission will decide the policy,” Lowe told Talbott firmly but politely. “You're always welcome [to provide] your legal opinion. But we need to make the policy decisions ourselves.”

Quixotically, Lowe then veered away from discussing the pending agenda item, seemingly to defend himself for not having spoken up at ARCI meetings against the crafting of these sorts of model rules.

“Don't ever think because Ken Lowe didn't vote against something [at an ARCI meeting] he voted for it,” Lowe said, referring to himself in the third person.

At the ARCI meetings, Lowe said, “I'm so damn outnumbered I feel like the lone ranger sitting there…. I think differently than many of these fine folks do.”

Talbott spoke up to tell Lowe that she never raised the issue of what Lowe did or didn't vote for at the ARCI level.

Lowe then diverged again, getting to what he said was the crux of the issue.

“The biggest point I have in this whole ordeal, to me, is the diminishing or doing away with Lasix, furosemide,” Lowe said. “I think that's one of the biggest travesties that's occurring in horse racing in this country right now. Because I've seen it. I've witnessed horses bleed. I've seen horses choke on their own blood. To do away with that is a fatal mistake.”

This time Lowe's digression was interrupted by WVRC executive director Joe Moore, who pointed out that Lasix isn't even included in the rules package that the board had up for a vote.

“The statement you just made has nothing to do with the three medication rules that are before this commission to vote on today, correct?” Moore asked. Talbott confirmed that Lasix was not up for any sort of vote.

After the conversation got steered back to the agenda item, Lowe asked if any commissioner would make a motion to either support or quash the proposed model rules.

Commissioner J.B. Akers moved to advance the rules package to the legislature, noting that last year, he was the only commissioner who supported essentially the same proposal.

“I know West Virginia is not New York or Kentucky or California. I realize that these rules, to some extent, can be more onerous on the horsemen in this state,” Akers said. “I realize that some people don't like these rules. But we're the only state in our region that has not adopted these model rules.”

Commissioner Tony Figaretti voted in favor of the motion with Akers. Lowe asked if there was any opposition, then said, “Hearing none, the motion passes,” without casting his own audible voice vote.

The post West Virginia Advances Model Rules; 2022 Implementation Hinges On Legislature appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

View From The Eighth Pole: Keeping HISA Out Of Racingā€™s Alphabet Soup

The Horseracing Integrity and Safety Authority (HiSA) got off to a solid start last month when Maryland attorney Charles Scheeler was elected by fellow directors to chair the nine-person board that will act as an independent oversight body on medication and safety issues for Thoroughbred racing in the United States.

The board includes some names that should be familiar to horse racing people (i.e., former Breeders' Cup and National Thoroughbred Racing Association executive D.G. Van Clief Jr., retired Keeneland president Bill Thomason, former New York Racing Association chief financial officer and president Ellen McClain, and Joseph De Francis, whose family previously owned Maryland tracks Laurel and Pimlico).

But there are others who bring major league sports experience to the Authority. Adolpho Birch spent 23 years at the National Football League's headquarters focusing on enforcement of integrity and drug issues, while Leonard Coleman served as president of Major League Baseball's National League (and is a former member of the Churchill Downs Inc. board of directors).

From the world of politics comes board member Steve Beshear, who served as Kentucky's attorney general, lieutenant governor and governor (his son Andy is Kentucky's current governor). Dr. Susan Stover from the University of California at Davis has blazed a trail of ground-breaking research on equine injuries and prevention. Scheeler played a significant role in Major League Baseball's Mitchell Report, which investigated the use of performance-enhancing drugs in that sport.

It is an outstanding group with a variety of skill sets that should work well together as the industry moves into uncharted waters with the development of national rules on medication and safety issues that will require the approval of the Federal Trade Commission in Washington, D.C.

The Authority's second step from the gate was a stumble ā€“ temporarily it is hoped ā€“ with the appointment of industry organization veteran Hank Zeitlin as interim executive director. Zeitlin is like that retread football coach with a mediocre record who keeps finding new teams to give him a chance. He's gone from management positions at The Jockey Club, to Equibase, to the Thoroughbred Racing Associations of North America in an undistinguished manner.

I'm going to take Scheeler's word for it that Zeitlin is being hired on an interim basis only ā€“ that Zeitlin's institutional knowledge will be somewhat useful as Scheeler and other board members get up to speed. He is not the person for the job long-term if the Authority is looking for a dynamic executive as its leader.

I'd almost forgotten that there still is a Thoroughbred Racing Associations of North America and that Zeitlin was collecting an industry paycheck from them. The TRA is not to be confused with the NTRA ā€“ the National Thoroughbred Racing Association. They are two distinct groups in racing's alphabet soup of organizations.

I'm not even sure what the TRA does any more, except to count and pass through the money its racetrack members earn for their ownership share of Equibase, the industry's official database that the TRA tracks co-own with The Jockey Club (TJC). Long ago, including during Zeitlin's tenure there as president, the Equibase board decided the company's primary role was to be profitable rather than to serve as a marketing and growth tool for Thoroughbred racing as almost all other sports use their historical data.

Does the industry still need the TRA? Does it really need the NTRA? Can it get by without the Thoroughbred Owners and Breeders Association, or the Association of Racing Commissioners International?

This might be a good time for a downsized industry to look at consolidating some of these organizations and their responsibilities. TRA could probably outsource Zeitlin's current job as its executive vice president to an accountant. The Thoroughbred Racing Protective Bureau, a subsidiary of TRA that once served as an important integrity and security division for horse racing, may fulfill some role in connection with the Authority, particularly when it comes to wagering security, the primary area in which the TRPB is now involved.

The NTRA is a ghost of what it was originally designed to be when it was established nearly 25 years ago. Having long ago given up on being a ā€œleague officeā€ for horse racing, the NTRA in recent years has focused on lobbying in Washington, D.C., running a profitable handicapping tournament, and presenting the Eclipse Awards. With NTRA president Alex Waldrop announcing that he will retire at year's end, this might be an opportune time to divvy up those responsibilities to existing groups like The Jockey Club or Equibase and save some money on salaries.

Same goes for the Thoroughbred Owners and Breeders Association (TOBA), whose only real purpose is the grading of North American stakes. Since The Jockey Club prepares the statistical data at TOBA's behest for the annual grading process, that responsibility could easily be transferred. TOBA has been operating in the red in recent years, with its chief executive taking home roughly 30% of the organization's annual revenue.

And what about the Association of Racing Commissioners International (ARCI)? Its primary function seems to be the development of model rules for a variety of activities in racing, including medication and safety policies. With those two categories falling under the Authority's umbrella, there will be a lot less meat on the bone for ARCI president Ed Martin to chew on.

Nothing will change, of course. Some of these organizations with uninspired leadership have evolved into nothing more than jobs programs, and they're not going away. Racing cannot afford to let the Horseracing Integrity and Safety Authority (HISA) be steered toward mediocrity and become just another ingredient in racing's bland alphabet soup. Its success is too important.

That's my view from the eighth pole.

The post View From The Eighth Pole: Keeping HISA Out Of Racing’s Alphabet Soup appeared first on Horse Racing News | Paulick Report.

Source of original post

NY Aligns Clenbuterol Policy With RMTCā€™s

The New York State Gaming Commission (NYSGC) uninimoulsy voted to adopt two Thoroughbred-related medication rule changes at its May 17 meeting, although the exact timetable for implementation was not discussed.

Pending official adoption of the new rule, clenbuterol use in Thoroughbred racing will be regulated so it follows the model rule proposal of the Racing Medication and Testing Consortium (RMTC).

“Clenbuterol, a drug that is ordinarily used in horses as a bronchodilator to treat horses with lower airway disease, also causes a horse's body to build more muscle and reduce its fat content and has the potential to enhance performance,” NYSGC general counsel Edmund Burns wrote in a brief included in the informational packet for Monday's meeting.

Burns wrote that the newly amended NYSGC rules “would require the attending veterinarian to receive written approval [from] the Commission of a clenbuterol treatment plan for an identified horse prior to the start of such treatment. The proposal would also require that all clenbuterol administrations be reported to the Commission at the time of administration.

“The proposal would also require horses treated with clenbuterol to be placed on the veterinarian's list and not be removed until a workout for a regulatory veterinarian is performed and the horse is found to be negative for clenbuterol in blood and urine.

“In addition, horses on the veterinarian's list for clenbuterol use would be required to submit to periodic tests while on such list to ensure that no more clenbuterol is administered to the horse than necessary to complete the pre-approved treatment

regimen and to ensure that muscle-building and fat-reducing effects have dissipated before the horse is removed from the veterinarian's list,” Burns wrote.

A second rule conforms the NYSGC rules on thresholds for controlled therapeutic medications to national model rules of the Association of Racing Commissioners International, Inc. (ARCI).

“ARCI modified the model rule thresholds for three drugs (detomidine, omeprazole and xylazine) based on developing research,” Burns wrote. “ARCI also added to the list of thresholds amounts for another four routine therapeutic medications, three of which are antihistamines (cetirizine, cimetidine and ranitidine) and one of which is a muscle relaxant used in anesthetic protocols (guaifensin). The thresholds are consistent with New York's existing restricted time periods. Trainers who comply with such restricted time periods will be assured of not violating such thresholds.”

The post NY Aligns Clenbuterol Policy With RMTC’s appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

CHRB Files Medication Complaints Against Hall Of Famers McAnally, Mandella

The California Horse Racing Board has filed medication complaints against trainers Ron McAnally and Richard Mandella, two members of the National Museum of Racing and Hall of Fame who have rarely been cited for violations throughout their careers.

McAnally was notified of a positive test for the Class 1 drug 7-Carboxy-Cannabidiol in Roses and Candy, winner of the third race at Del Mar on Nov. 22, 2020. A split sample confirmed the presence of the substance.

Better known as CBD, Cannabidiol is found in a number of equine products, including tincture oil, pellets, liniment spray and poultices. While it is believed to work as an anti-inflammatory there is limited research on the possible benefits of CBD in horses and its use remains controversial. Because it is not included in the CHRB's classification list of drugs, it becomes a Class 1/Penalty Class A by default, according to CHRB spokesman Mike Marten.Ā  The Association of Racing Commissioners International lists Cannabidiol as a Class 2/Penalty Category B substance.

Marten said a proposed rule change to make Cannabidiol a Class 3/Penalty Category B drug is currently out for public comment and CHRB executive director Scott Chaney and investigators will recommend that stewards treat the alleged infraction as a Class 3 violation. It would still result in the disqualification of the horse, Marten added.

McAnally has not been sanctioned for any medication violations in California since 1998, Marten said. According to www.thoroughbredrulings.com, McAnally received a warning for a positive test for the Class D drug Cimetidine in Kentucky in 2009.

The CHRB filed a complaint against Mandella on May 7 after Jolie Olimpica ā€“ third in the Grade 3 San Simeon Stakes on March 13, 2021 ā€“ was found in a post-race sample to have 6.1 ng/ml of the Class 4/Penalty Category C drug methocarbamol ā€“ a muscle relaxant.Ā  A split sample confirmed the presence of the drug.

Mandella was fined $500 in January 2018 after two anti-inflammatories were found in a post-race sample ā€“ his most recent violation. He was also fined $500 for a methocarbamol positive in 2011.

Stewards hearings will be scheduled for both trainers.

The post CHRB Files Medication Complaints Against Hall Of Famers McAnally, Mandella appeared first on Horse Racing News | Paulick Report.

Source of original post

Verified by MonsterInsights